Certified by Founder Lodge
Glycomine Inc.
United States - San Carlos, California
START UP
1 Disclosed Funding Rounds $115,000,000
0 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| April, 17 ,2025 | Series C | $115,000,000 |
Advent Life Sciences
Abingworth
RiverVest Venture Partners
CTI Life Sciences Fund
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
AIRRIVED | $6,100,000 | (Feb 4, 2026)
Derapi | $7,000,000 | (Feb 4, 2026)
Arbor(US) | $6,300,000 | (Feb 4, 2026)
Graici | $7,500,000 | (Feb 4, 2026)
enclaive | $4,849,418 | (Feb 4, 2026)
